Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs JNJ 64400141 (Primary) ; JNJ-64213175 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Vaccines and Prevention B.V
- 11 Jul 2023 Results assessing safety immunogenicity and regimen selection of Ad26.RSV.preF-based Vaccine published in the Journal of Infectious Diseases
- 02 Aug 2022 Status changed from active, no longer recruiting to completed.
- 19 Feb 2021 Planned primary completion date changed from 30 Apr 2021 to 30 May 2022.